Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of cancer called gastroesophageal junction adenocarcinoma (Siewert II or III) that has not spread to other organs.
- Your cancer is considered resectable (can be removed by surgery) and is at a certain stage (T3-4N0M0 or T1-4N+M0).
- You have not had any prior cancer treatment (like surgery, chemo, or radiation) for this condition.
- You are in good general health, able to do daily activities without much help (ECOG 0 or 1), and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
This trial studies giving immunotherapy together with chemotherapy and radiation before surgery for esophagogastric junction cancer. It aims to shrink the tumor and improve outcomes for people with early locally advanced, HER2-negative disease.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Hear when a new Gastroesophageal Junction Adenocarcinoma (Siewert II-III) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.